Pierre Fabre Adopts Veeva OpenData to Enhance Commercial Execution

(NYSE:VEEV) today announced global pharmaceutical and
dermo-cosmetics company Pierre
adopted Veeva
for accurate customer data to strengthen healthcare
professional (HCP) engagement for its dermo-cosmetics business. Building
on its success with Veeva
, the company will now have reliable, complete customer data to
help medical representatives deliver greater value in HCP interactions.

“We wanted to give our medical reps around the world access to high
quality customer data,” said Vincent Lacour, program manager at Pierre
Fabre. “Veeva OpenData will enable them to target customers more
effectively and deliver the right message at the right time.”

With hundreds of reps in 22 countries across Europe, North America,
South America, and Australia, Pierre Fabre wanted to standardize on one
global solution for customer data. Veeva OpenData gives teams easy
access to an accurate view of their customers to drive smarter, informed
interactions. To maintain productivity, reps can submit data change
requests (DCRs) directly to Veeva’s global team of expert data stewards
that validate and update DCRs within hours.

“Veeva responds to change requests and verifies updates to customer data
quickly,” added Vincent Lacour, program manager at Pierre Fabre. “Veeva
OpenData ensures our reps are working with accurate information to stay
productive, compliant, and focused on the customer.”

Organizations from emerging biotechs to the largest pharmaceutical
companies are using Veeva OpenData, which provides access to
approximately 16 million HCPs and their healthcare organizations
spanning 42 countries. Leading companies, including 16 of the top 20
pharmaceutical companies, have made
the switch to Veeva OpenData
 in various regions to increase field
effectiveness and enhance customer engagement.

“Pierre Fabre is implementing an innovative global strategy to
strengthen customer relationships for its dermo-cosmetics business,”
said Guillaume Roussel, director of strategy, Veeva OpenData, Europe.
“Veeva OpenData will give the company real-time access to accurate
customer information to improve commercial execution.”

Hear why Pierre Fabre and other customers are making the switch to Veeva
OpenData at the upcoming Veeva
Commercial Medical Summit, Europe
, December 3-5, in Madrid,
Spain. Learn more, register, and view the full agenda at veeva.com/eu/summit.

Additional Information

For more information on Veeva OpenData, visit: veeva.com/eu/VeevaOpenData

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

Follow @veeva_EU on Twitter: twitter.com/veeva_EU

Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 675 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,
visit veeva.com/EU.

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended July 31, 2018. This is available on the
company’s website at veeva.com/eu
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to